Nuclear Medicine & Positron Emission Tomography

As the pioneer in local PET services, we have gained substantial experience and been leading the local industry for more than 20 years. The combined utility of multiple tracers is our belief on the core clinical applications of nuclear medicine and PET/CT imaging, which is unique and able to provide valuable diagnostic information. In addition to modern medical cyclotron, licensed radiopharmacy laboratory, efficient synthesizer, high-end chemical technology and quality assurance laboratory, professional teams comprising of chartered chemist and pharmacist are indispensable elements to clinical services and continuous development. Therefore, we have devoted lots of resources to develop tracer production and supply services, and continue to update technology and upgrade laboratory facility. 

Our facility is fully licensed by the Department of Health of the Government of HKSAR for production and sales of PET tracers; accredited by the Australian Council on Healthcare Standards (ACHS); and certified by the National Medical Products Administration (NMPA) in collaboration with our Clinical Oncology Centre as the only private medical institution in Hong Kong for conducting clinical trials for human used drugs. With more than 20 years of experiences and unparalleled expertise, the team proactively source the latest and useful radiopharmaceutical around the world and import to Hong Kong. We also supply PET tracers to other local clinical centres, indicating that we are fully trusted and affirmed by the community. 

Radiopharmaceutical supplies services are operated by a dedicated team of nuclear medicine specialists, radiochemists and radiographers. Our production facilities include 4 medical cyclotrons, 2 radiopharmacy laboratories and a quality control laboratory. All productions are in accordance with international guidelines including “Current Good Manufacturing Practice” (cGMP) and “Current Good Radio-Pharmacy Practice” (cGRPP). Our team is specialized in synthesizing close to 20 radiopharmaceuticals tagged with F-18, C-11 or Ga-68 for clinical use. Oncologists can obtain critical and valuable information to prescribe the most suitable treatment regime for patients, such as radiotherapy planning and radionuclide therapy. While some local centres are now at initial stage in radiopharmaceutical production, we, as a pioneer in local NM and PET services, maintain a solid lead with continuous upgrades in knowledge, equipment and techniques. 

Apart from the most common F-18 FDG, the clinical use of non-FDG tracers such as C-11 acetate and F-18 PSMA have been proven for non-glucose dependent malignancies such as liver, kidney and prostate. Diversified NM and PET tracers have also enabled the evaluation and treatment of metabolic disease (such as neuroendocrine tumour) which is used to be difficult. All these open a new horizon for therapy strategy.